Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)

NCT03984214 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT03984214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03984214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2019
Completion date
September 25, 2024
Enrollment
109 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting, pancreatic cancer metastatic, pancreatic cancer non-resectable